Furthermore, the combination of FXR agonists and GLP-2 analogues may also be attractive for patients suffering from PSC accompanied by inflammatory bowel disease, because it has been shown that GLP-2 treatment has anti-inflammatory effects in a mouse model of inflammatory bowel disease.21 This evidence concerns the gene NR1H4 and inflammatory bowel disease.